Is Statin-Induced Myositis Part of the Polymyositis Disease Spectrum?
- 942 Downloads
Statin medications have recently been shown to cause not only a toxic myopathy but also an immune-mediated necrotizing myositis. Before the discovery of a specific anti-HMG-CoA reductase antibody occurring in conjunction with a necrotizing myopathy, many of these patients may have been classified as polymyositis. They present similarly with proximal muscle weakness, elevated muscle enzymes, persistence of symptoms despite cessation of the statin, with need for immunosuppression. This article provides an overview of this novel disease entity by placing it in the context of existing idiopathic inflammatory myopathy (IIM) classification criteria, and in the range of statin-associated muscle toxicity.
KeywordsStatin myopathy Anti-HMG CoA reductase Polymyositis Necrotizing myopathy Classification criteria IMNM
Compliance With Ethics Guidelines
Conflict of Interest
Jemima Albayda declares that she has no conflict of interest. Andrew L. Mammen reports grants from NIH during the conduct of the study. In addition, Dr Mammen has patented an anti-HMGCR antibody test from which he is entitled to receive royalties from INOVA Diagnostics.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337–45.PubMedCrossRefGoogle Scholar
- 13.•Preuße C, Goebel HH, Held J, Wengert O, Scheibe F, Irlbacher K, et al. Immune-Mediated Necrotizing Myopathy Is Characterized by a Specific Th1-M1 Polarized Immune Profile. Am J Pathol. 2012;181(6):2161–71. This study demonstrated that a difference in cellular and molecular characteristics can distinguish immune-mediated necrotizing myopathies from non-immune-mediated necrotizing myopathies.PubMedCrossRefGoogle Scholar
- 15.Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, et al. Autoantibodies in Polymyositis and Dermatomyositis. Curr Rheumatol Rep [Internet]. 2013. [cited 2014 May 21];15(6). Available from: 10.1007/s11926-013-0335-1
- 18.Tansley S, Gunawardena H. The Evolving Spectrum of Polymyositis and Dermatomyositis—Moving Towards Clinicoserological Syndromes: A Critical Review. Clin Rev Allergy Immunol [Internet]. 2013. [cited 2014 Mar 1]; Available from: http://link.springer.com/ 10.1007/s12016-013-8387-6
- 20.Milisenda JC, Selva-O’Callaghan A, Grau JM. The diagnosis and classification of polymyositis. J Autoimmun [Internet]. 2014 [cited 2014 Mar 1]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0896841114000286
- 27.SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study. N Engl J Med. 2008;359(8):789–99.Google Scholar
- 33.•Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–21. This study identified the autoantigen involved in statin-associated autoimmune myopathy and provided a mechanistic link between the drug and development of sustained autoimmunity.PubMedCentralPubMedCrossRefGoogle Scholar
- 34.•Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res. 2012;64(2):269–72. This study demonstrated that anti-HMGCR is infrequently seen in patients who take statins, including those with self-limited statin intolerance, and is specific for an autoimmune myopathy.CrossRefGoogle Scholar
- 35.•Mammen AL, Gaudet D, Brisson D, Christopher-Stine L, Lloyd TE, Leffell MS, et al. Increased frequency of DRB1*11:01 in anti-HMG-CoA reductase-associated autoimmune myopathy. Arthritis Care Res. 2012;1233–7. This study identified class II HLA loci that confer susceptibility to and protection from anti-HMGCR myopathy. Google Scholar
- 36.Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64(12):4087–93.PubMedCentralPubMedCrossRefGoogle Scholar